In short
This article discusses the ongoing clinical trials of MEN1703, a new drug being tested for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. MEN1703, also known as 5,6-Dibromo-4-Nitro-2-Piperidin-4-Yl-1-Propan-2-Ylbenzimidazole, is being studied both as a standalone treatment and in combination with another drug called glofitamab. These trials aim to evaluate the safety, effectiveness, and potential benefits of MEN1703 for patients who have not responded well to previous treatments.
At a glance
- Drug Name
- MEN1703 (5,6-Dibromo-4-Nitro-2-Piperidin-4-Yl-1-Propan-2-Ylbenzimidazole)
- Condition Studied
- Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
- Trial Phase
- Phase II
- Treatment Groups
- 1) MEN1703 + Glofitamab, 2) MEN1703 monotherapy
- Dosing
- Oral capsules, 125-150 mg daily for 7-14 days in 21-day cycles
- Primary Objectives
- Safety, tolerability, and anti-lymphoma activity
- Key Eligibility
- Adults with confirmed diagnosis, ≥2 prior treatments, adequate organ function
- Primary Endpoints
- Adverse events, Complete Response Rate, Overall Response Rate
What is MEN1703?
MEN1703 is an investigational drug being studied for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Its chemical name is 5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole. This medication is being developed by Menarini Ricerche S.P.A. and is currently in Phase II clinical trials.
Target Condition: Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin lymphoma is a type of cancer that affects the lymphatic system, particularly the B-cells, which are a type of white blood cell. When the disease is described as "relapsed," it means the cancer has returned after initial treatment. "Refractory" indicates that the cancer has not responded to standard treatments. The "aggressive" nature of this lymphoma means it tends to grow and spread quickly, making it a challenging condition to treat.
How MEN1703 Works
While the exact mechanism of action is not fully detailed in the provided information, MEN1703 is being studied as a PIM inhibitor. PIM kinases are enzymes that play a role in cell survival and proliferation, and their inhibition may help slow down or stop the growth of cancer cells.
Clinical Trial Details
The clinical trial for MEN1703 (known as JASPIS-01) is an open-label, Phase 2 study. It is evaluating MEN1703 both as a standalone treatment (monotherapy) and in combination with another drug called glofitamab. The study aims to assess:
- The safety and tolerability of MEN1703
- Its effectiveness against lymphoma (anti-lymphoma activity)
- How the drug behaves in the body (pharmacokinetics)
- The impact on patients' quality of life and symptoms
Dosage and Administration
MEN1703 is taken orally in the form of capsules. The study is exploring different dosing regimens:
- 150 mg daily for 7 consecutive days in 21-day cycles
- 125 mg daily for 14 consecutive days in 21-day cycles
The medication is available in 25 mg and 100 mg capsules.
Potential Benefits
The primary goals of the study include evaluating:
- Complete Response (CR) rate: This measures how many patients experience a complete disappearance of all detectable cancer.
- Overall Response Rate (ORR): This includes both complete and partial responses to the treatment.
- Duration of Response (DoR): How long the beneficial effects of the treatment last.
- Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
- Overall survival (OS): The length of time from the start of treatment that patients are still alive.
Eligibility Criteria
Key eligibility criteria for participating in the MEN1703 clinical trial include:
- Age 18 or older
- Confirmed diagnosis of aggressive B-cell non-Hodgkin lymphoma
- Have received at least 2 prior lines of systemic treatment
- Adequate organ function and performance status
Patients with certain conditions, such as active central nervous system involvement, recent stem cell transplant, or certain autoimmune diseases, may not be eligible.
Safety Considerations
As with any investigational drug, there may be unknown risks and side effects. The study closely monitors for adverse events. Some areas of particular focus include:
- Liver function
- Heart function
- Blood cell counts
- Potential drug interactions
Patients in the trial will be closely monitored for any side effects or safety concerns throughout their participation.